Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Environ Sci Technol ; 58(26): 11292-11300, 2024 Jul 02.
Artigo em Inglês | MEDLINE | ID: mdl-38888518

RESUMO

Aluminum (Al) is the most abundant metal in the earth's crust, and humans are exposed to Al through sources like food, cosmetics, and medication. So far, no comprehensive data on the Al distribution between and within human tissues were reported. We measured Al concentrations in 24 different tissue types of 8 autopsied patients using ICP-MS/MS (inductively coupled plasma-tandem mass spectrometry) under cleanroom conditions and found surprisingly high concentrations in both the upper and inferior lobes of the lung and hilar lymph nodes. Al/Si ratios in lung and hilar lymph node samples of 12 additional patients were similar to the ratios reported in urban fine dust. Histological analyses using lumogallion staining showed Al in lung erythrocytes and macrophages, indicating the uptake of airborne Al in the bloodstream. Furthermore, Al was continuously found in PM2.5 and PM10 fine dust particles over 7 years in Upper Austria, Austria. According to our findings, air pollution needs to be reconsidered as a major Al source for humans and the environment.


Assuntos
Alumínio , Pulmão , Linfonodos , Humanos , Pulmão/metabolismo , Exposição Ambiental , Poluentes Atmosféricos , Poeira , Masculino , Feminino , Material Particulado , Áustria , Pessoa de Meia-Idade
2.
Hautarzt ; 71(1): 57-62, 2020 Jan.
Artigo em Alemão | MEDLINE | ID: mdl-31420711

RESUMO

Sebaceous carcinoma in situ (SCIS) is a rare intraepidermal neoplasia, mostly occurring on the eyelid and the face. Despite abundant literature on invasive sebaceous carcinoma, there are relatively few articles about SCIS. We report the case of 78-year-old woman suffering from SCIS of the left cheek, presenting as an erythematous skin lesion. The histological examination revealed intraepidermal and intraadnexal population of atypical cells with foamy cytoplasm and with immunohistochemical adipophilin-, cytokeratin-7- and EMA-positivity in the tumor cells.


Assuntos
Adenocarcinoma Sebáceo , Carcinoma in Situ , Neoplasias das Glândulas Sebáceas , Neoplasias Cutâneas , Adenocarcinoma Sebáceo/diagnóstico , Idoso , Carcinoma in Situ/diagnóstico , Feminino , Humanos , Perilipina-2 , Neoplasias das Glândulas Sebáceas/diagnóstico , Neoplasias Cutâneas/diagnóstico
3.
J Anat ; 234(1): 33-42, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30411352

RESUMO

Only a few papers exist dealing with the development and aging of the autonomic nervous system - and even rarer are studies that investigated the otic ganglion. Using a special trepan, we removed and investigated 172 samples from 86 corpses, ranging from 20 weeks of gestational age (GA) to 95 years of age. The aim of the study was to measure different morphometric parameters of the ganglionic neurons in order to study age-related changes from early development until old age. Fetuses show the highest numerical density of neurons. Then, in the first years of life, a rapid growth of the cytoplasm takes place, which is the main reason for the neuronal growth and the increase of the general size of the otic ganglion at this age. Also, the number of satellite cells increases till puberty. In adults, the parameters are relatively stable over decades and decrease slowly, in contrast to the steep increase in the first years of life. Moreover, neuronal degeneration, storage of pigments, neuro-axonal dystrophy, and lymphocytic infiltrates increase with age.


Assuntos
Desenvolvimento Embrionário/fisiologia , Gânglios Parassimpáticos/crescimento & desenvolvimento , Gânglios Parassimpáticos/ultraestrutura , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Adulto Jovem
4.
Acta Oncol ; 58(7): 967-976, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-30994047

RESUMO

Background: Primary CNS lymphoma is a highly aggressive and rare type of extranodal non-Hodgkin lymphoma. Although, new therapeutic approaches have led to improved survival, the management of the disease poses a challenge, practice patterns vary across institutions and countries, and remain ill-defined for vulnerable patient subgroups. Material and Methods: Using information from the Austrian Brain Tumor Registry we followed a population-based cohort of 189 patients newly diagnosed from 2005 to 2010 through various lines of treatment until death or last follow-up (12-31-2016). Prognostic factors and treatment-related data were integrated in a comprehensive survival analysis including conditional survival estimates. Results: We find variable patterns of first-line treatment with increasing use of rituximab and high-dose methotrexate (HDMTX)-based poly-chemotherapy after 2007, paralleled by an increase in median overall survival restricted to patients aged below 70 years. In the entire cohort, 5-year overall survival was 24.4% while 5-year conditional survival increased with every year postdiagnosis. Conclusion: In conclusion, we show that the use of poly-chemotherapy and immunotherapy has disseminated to community practice to a fair extent and survival has increased over time at least in younger patients. Annually increasing conditional survival rates provide clinicians with an adequate and encouraging prognostic measure.


Assuntos
Antineoplásicos Imunológicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Linfoma não Hodgkin/tratamento farmacológico , Adolescente , Adulto , Idoso , Áustria/epidemiologia , Neoplasias Encefálicas/mortalidade , Feminino , Seguimentos , Humanos , Linfoma não Hodgkin/mortalidade , Masculino , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Prognóstico , Intervalo Livre de Progressão , Sistema de Registros/estatística & dados numéricos , Rituximab/uso terapêutico , Análise de Sobrevida , Adulto Jovem
5.
J Neurol ; 271(7): 4095-4104, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38578497

RESUMO

BACKGROUND AND PURPOSE: Cerebral sinus venous thrombosis (CSVT) is a rare but life-threatening disease and its diagnosis remains challenging. Blood biomarkers, including D-Dimer are currently not recommended in guidelines. Soluble endothelial receptor proteins (sICAM-1, sPECAM-1 and sVCAM-1) have been shown to be promising diagnostic biomarkers in deep vein thrombosis (DVT) and pulmonary embolism (PE). Therefore, we examined endothelial receptor proteins as potential biomarkers for detecting CSVT. METHODS: In this bi-centre, prospective study, we quantified D-Dimer as well as sICAM-1, sPECAM-1 and sVCAM-1 in plasma of patients with clinically suspected CSVT managed in the neurological emergency department (ED) of a tertiary care hospital. All patients underwent cerebral magnetic resonance imaging (MRI) and were followed up after 3, 6 and 12 months to detect thrombus resolution. RESULTS: Twenty-four out of 75 (32%) patients with clinically suspected CSVT presenting with headache to the ED were diagnosed with acute CSVT. These patients had a mean age of 45 ± 16 years and 78% were female. In patients with CSVT, mean baseline D-dimer (p < 0.001) and sPECAM-1 (p < 0.001) were significantly higher compared to patients without CSVT. The combination of D-Dimer and sPECAM-1 yielded the best ROC-AUC (0.994; < 0.001) with a negative predictive value of 95.7% and a positive predictive value of 95.5%. In addition, higher baseline sPECAM-1 levels (> 198 ng/ml) on admission were associated with delayed venous thrombus resolution at 3 months (AUC = 0.83). CONCLUSION: sPECAM-1 in combination with D-Dimer should be used to improve the diagnostic accuracy of acute CSVT and sPECAM-1 may predict long-term outcome of CSVT. Confirmatory results are needed in other settings in order to show their value in the management concept of CSVT patients.


Assuntos
Produtos de Degradação da Fibrina e do Fibrinogênio , Trombose dos Seios Intracranianos , Trombose Venosa , Humanos , Feminino , Masculino , Pessoa de Meia-Idade , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Trombose dos Seios Intracranianos/sangue , Trombose dos Seios Intracranianos/diagnóstico por imagem , Adulto , Estudos Prospectivos , Trombose Venosa/sangue , Trombose Venosa/diagnóstico por imagem , Biomarcadores/sangue , Imageamento por Ressonância Magnética , Molécula 1 de Adesão Intercelular/sangue , Seguimentos , Idoso
6.
Cancers (Basel) ; 12(6)2020 Jun 16.
Artigo em Inglês | MEDLINE | ID: mdl-32560244

RESUMO

Sex-specific differences have been increasingly recognized in many human diseases including brain cancer, namely glioblastoma. Primary CNS lymphoma (PCNSL) is an exceedingly rare type of brain cancer that tends to have a higher incidence and worse outcomes in male patients. Yet, relatively little is known about the reasons that contribute to these observed sex-specific differences. Using a population-representative cohort of patients with PCNSL with dense magnetic resonance (MR) imaging and digital pathology annotation (n = 74), we performed sex-specific cluster and survival analyses to explore possible associations. We found three prognostically relevant clusters for females and two for males, characterized by differences in (i) patient demographics, (ii) tumor-associated immune response, and (iii) MR imaging phenotypes. Upon a multivariable analysis, an enhanced FoxP3+ lymphocyte-driven immune response was associated with a shorter overall survival particularly in female patients (HR 1.65, p = 0.035), while an increased extent of contrast enhancement emerged as an adverse predictor of outcomes in male patients (HR 1.05, p < 0.01). In conclusion, we found divergent prognostic constellations between female and male patients with PCNSL that suggest differential roles of tumor-associated immune response and MR imaging phenotypes. Our results further underline the importance of continued sex-specific analyses in the field of brain cancer.

7.
Front Immunol ; 9: 108, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29441072

RESUMO

Immune checkpoint inhibitors are antibodies, which enhance cellular and humoral immune responses and are approved for the treatment of various tumors. Immune-related adverse events (irAE) involving different organs and systems are, however, among the side-effects. Recent reports of severe persistent neurological deficits and even fatal cases underpin the need for better understanding of the exact pathomechanisms of central nervous system (CNS) toxicity. To our knowledge, we report the first biopsy-proven case of fatal necrotizing encephalopathy after treatment with nivolumab. Nivolumab targets the immune-check point inhibitor programmed cell death-1 and was used for squamous non-small cell lung cancer. Partly reversible neurologic and psychiatric symptoms and unremarkable brain magnetic resonance imaging (MRI) were observed after the first course. Neurological symptoms progressed and recurrent seizures developed after the second course. Brain MRI disclosed multiple edematous and confluent supra- and infratentorial lesions, partly with contrast-enhancement. We excluded autoimmune and paraneoplastic causes and performed ancillary investigations to rule out common and opportunistic infections. Eventually, postmortem histopathological analysis of the brain revealed a necrotizing process, which contrasts previous cases reporting parenchymal immune cell infiltration or demyelination. Appropriate diagnostic pathways and treatment algorithms need to be implemented for the work-up of CNS toxicity and irAEs related to immune checkpoint inhibitor treatment.


Assuntos
Antineoplásicos Imunológicos/efeitos adversos , Encefalopatias/induzido quimicamente , Nivolumabe/efeitos adversos , Idoso , Encéfalo/diagnóstico por imagem , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Encefalopatias/diagnóstico por imagem , Encefalopatias/patologia , Carcinoma Pulmonar de Células não Pequenas/diagnóstico por imagem , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/patologia , Evolução Fatal , Feminino , Humanos , Neoplasias Pulmonares/diagnóstico por imagem , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA